Literature DB >> 29239793

Medical societies, patient education initiatives, public debate and marketing of unproven stem cell interventions.

Daniel J Weiss1, Leigh Turner2, Aaron D Levine3, Laertis Ikonomou4.   

Abstract

Businesses marketing unproven stem cell interventions proliferate within the U.S. and in the larger global marketplace. There have been global efforts by scientists, patient advocacy groups, bioethicists, and public policy experts to counteract the uncontrolled and premature commercialization of stem cell interventions. In this commentary, we posit that medical societies and associations of health care professionals have a particular responsibility to be an active partner in such efforts. We review the role medical societies can and should play in this area through patient advocacy and awareness initiatives.
Copyright © 2017 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  health care professionals; medical societies; patients; unproven stem cell interventions; “stem cell” clinics

Mesh:

Year:  2017        PMID: 29239793     DOI: 10.1016/j.jcyt.2017.10.002

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  2 in total

Review 1.  Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions.

Authors:  Gerhard Bauer; Magdi Elsallab; Mohamed Abou-El-Enein
Journal:  Stem Cells Transl Med       Date:  2018-07-31       Impact factor: 6.940

2.  The involvement of Canadian physicians in promoting and providing unproven and unapproved stem cell interventions.

Authors:  Ubaka Ogbogu; Jenny Du; Yonida Koukio
Journal:  BMC Med Ethics       Date:  2018-05-02       Impact factor: 2.652

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.